NASDAQ:LPCN Lipocine (LPCN) Stock Price, News & Analysis $3.66 -0.08 (-2.14%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$3.53▼$3.7450-Day Range$3.52▼$8.2452-Week Range$2.31▼$11.79Volume13,167 shsAverage Volume50,491 shsMarket Capitalization$19.57 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Lipocine alerts: Email Address Lipocine MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy2.72% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.92) to ($0.93) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.06 out of 5 starsMedical Sector903rd out of 909 stocksPharmaceutical Preparations Industry424th out of 426 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Lipocine.Read more about Lipocine's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.72% of the float of Lipocine has been sold short.Short Interest Ratio / Days to CoverLipocine has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lipocine has recently increased by 21.79%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLipocine does not currently pay a dividend.Dividend GrowthLipocine does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LPCN. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Lipocine this week, compared to 0 articles on an average week.Search Interest2 people have searched for LPCN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows18 people have added Lipocine to their MarketBeat watchlist in the last 30 days. This is an increase of 800% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lipocine insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.12% of the stock of Lipocine is held by insiders.Percentage Held by InstitutionsOnly 9.11% of the stock of Lipocine is held by institutions.Read more about Lipocine's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Lipocine are expected to decrease in the coming year, from ($0.92) to ($0.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lipocine is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lipocine is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLipocine has a P/B Ratio of 0.92. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Lipocine's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << About Lipocine Stock (NASDAQ:LPCN)Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.Read More LPCN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LPCN Stock News HeadlinesSeptember 5 at 8:00 AM | prnewswire.comLipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®August 31, 2024 | americanbankingnews.comLipocine (NASDAQ:LPCN) Downgraded by StockNews.com to HoldSeptember 7, 2024 | Behind the Markets (Ad)⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.August 27, 2024 | prnewswire.comLipocine to Present at H.C. Wainwright 26th Annual Global Investment ConferenceAugust 8, 2024 | prnewswire.comLipocine Announces Financial Results for the Second Quarter Ended June 30, 2024August 2, 2024 | theglobeandmail.comPostpartum Depression Drugs Market Size Report 2034 | Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, TalkspaceJune 25, 2024 | prnewswire.comLipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal StudyJune 10, 2024 | prnewswire.comLipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024September 7, 2024 | Paradigm Press (Ad)Ex-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…May 28, 2024 | investorplace.com7 Penny Biotech Stocks to Triple Your InvestmentMay 9, 2024 | investorplace.comLPCN Stock Earnings: Lipocine Beats EPS for Q1 2024May 9, 2024 | finance.yahoo.comLipocine Announces Financial Results for the First Quarter Ended March 31, 2024May 8, 2024 | prnewswire.comLipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024May 1, 2024 | prnewswire.comLipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154April 12, 2024 | msn.comLipocine hopes obesity drug could boost muscle mass in combo with GLP1-RAsApril 11, 2024 | finanznachrichten.deLipocine Inc.: Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with ObesityApril 11, 2024 | fr.investing.comLipocine annonce les résultats positifs d'une étude sur le traitement de l'obésitéApril 11, 2024 | markets.businessinsider.comLipocine Reports Positive Phase 2 Results For LPCN 2401 In Participants With ObesitySee More Headlines Receive LPCN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LPCN CUSIPN/A CIK1535955 Webwww.lipocine.com Phone(801) 994-7383Fax801-994-7388Employees10Year Founded1997Profitability EPS (Most Recent Fiscal Year)($1.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,350,000.00 Net MarginsN/A Pretax Margin-176.76% Return on Equity-38.58% Return on Assets-35.28% Debt Debt-to-Equity RatioN/A Current Ratio12.56 Quick Ratio12.56 Sales & Book Value Annual Sales$4.80 million Price / Sales4.08 Cash FlowN/A Price / Cash FlowN/A Book Value$3.97 per share Price / Book0.92Miscellaneous Outstanding Shares5,348,000Free Float5,021,000Market Cap$19.57 million OptionableNo Data Beta1.12 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Mahesh V. Patel Ph.D. (Age 67)Co-Founder, Interim Principal Financial Officer, Director, President & CEO Comp: $762.53kMs. Krista Fogarty (Age 56)Principal Accounting Officer & Corporate Controller Comp: $321.07kDr. Nachiappan Chidambaram Ph.D. (Age 55)Senior Vice President of Research & Development Comp: $385.71kMr. Logan Morse (Age 54)Vice President of Sales, Marketing & Operations Comp: $413.58kKey CompetitorsChembio DiagnosticsNASDAQ:CEMIOrgenesisNASDAQ:ORGSLantern PharmaNASDAQ:LTRNChimerixNASDAQ:CMRXOvid TherapeuticsNASDAQ:OVIDView All CompetitorsInstitutional OwnershipRenaissance Technologies LLCBought 4,600 shares on 8/9/2024Ownership: 0.480%Dimensional Fund Advisors LPBought 11,870 shares on 8/9/2024Ownership: 0.222%View All Institutional Transactions LPCN Stock Analysis - Frequently Asked Questions How have LPCN shares performed this year? Lipocine's stock was trading at $2.79 at the beginning of 2024. Since then, LPCN stock has increased by 31.2% and is now trading at $3.66. View the best growth stocks for 2024 here. How were Lipocine's earnings last quarter? Lipocine Inc. (NASDAQ:LPCN) issued its earnings results on Thursday, August, 8th. The specialty pharmaceutical company reported ($0.56) earnings per share for the quarter. The specialty pharmaceutical company earned $0.09 million during the quarter. When did Lipocine's stock split? Lipocine shares reverse split on the morning of Friday, May 12th 2023. The 1-17 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. Who are Lipocine's major shareholders? Lipocine's top institutional investors include Renaissance Technologies LLC (0.48%) and Dimensional Fund Advisors LP (0.22%). Insiders that own company stock include Mahesh V Patel, Spyros Papapetropoulos, Richard Dana Ono and Krista Fogarty. View institutional ownership trends. How do I buy shares of Lipocine? Shares of LPCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Lipocine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lipocine investors own include Synergy Pharmaceuticals (SGYP), Flexion Therapeutics (FLXN), Trevena (TRVN), Heat Biologics (HTBX), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX). This page (NASDAQ:LPCN) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredThese 2 simple sentences turn every Friday into payday?Most people have never heard of Jim Fink. Behind his humble demeanor and insistence on personal privacy... ...Investing Daily | SponsoredHere’s A Painful Truth and 100% Fact About The Stocks You’re HoldingCharles Payne here, and I want to let you in on an uncomfortable truth that long term investors and retirees n...Unstoppable Prosperity | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipocine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipocine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
